• Significant revenue growth and diversification since FY23
• Expanded addressable global market across therapeutic areas
• Growth strategy bearing early fruit with cross-selling opportunities

Resonance Health Ltd's AGM presentation outlines the company's strong business transformation and growth trajectory. Since FY23, the company has achieved significant revenue growth of around 45% CAGR, and has diversified its revenue streams across multiple therapeutic areas. The company has expanded its addressable global market, now targeting opportunities in areas such as metabolic diseases, obesity, liver fibrosis, and clinical research organization (CRO) services, which collectively represent a market opportunity exceeding $1 trillion. The company's growth strategy of increasing its 'share of wallet' with existing customers, expanding into new therapeutic areas, and adding more customers and sites is bearing early fruit, with several cross-selling opportunities identified across its service offerings. The company is also exploring growth opportunities in its Software as a Medical Device (SaMD) business, geographic expansion of its TrialsWest CRO services, and potential acquisitive growth in the US and Europe to participate in larger phase 3 clinical trials. The company has provided FY26 guidance of around $17 million in revenue and $2 million in underlying operating EBITDA, with significant potential upside from conservative assumptions.

FY26 Guidance: Revenue $17M, Underlying Operating EBITDA $2M. Grow underlying EBITDA margins to ~12%, targeting ~25% over coming periods. Operationally cashflow positive.

Resonance Health is well-positioned for continued growth, with opportunities across its SaMD business, geographic expansion of TrialsWest, expansion into new therapeutic areas, and potential acquisitive growth in the US and Europe to participate in larger phase 3 clinical trials.